FindTrial
Sign In

To study the side effects and effectiveness effects of Tablet Ribociclib in hormone positive , HER2 negative breast cancer patients

Real life evidence of Tab Ribociclib for Safety and Efficacy in a tertiary care centre (RERISE study). - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061744
Enrollment
1000
Registered
2024-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Not applicable: Not applicable

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients with histopathologically confirmed ER or PR positive and HER2 negative locally advanced or metastatic breast cancer 2 Patients who have been started on Ribocliclib with atleast one record of treatment with Ribociclib from the year Jun 2018 till December 2022 will be included in study. Data will be collected from the EMR

Exclusion criteria

Exclusion criteria: 1. Patient with HER2 positive metastatic cancer. 2. Patients with no available data on EMR.

Design outcomes

Secondary

MeasureTime frame
To study safety and toxicity.Timepoint: 12 months—

Primary

MeasureTime frame
To study efficacy including Progression Free Survival and Overall SurvivalTimepoint: 12 months—

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Center

sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026